Drug Industry Looking For Ways To Prevent Future NDMA Contamination: Report

Over the past two years, a number of pharmaceutical products have been found to contain the cancer-causing chemical N-nitrosodimethylamine (NDMA), leading to massive recalls for Zantac, valsartan, metformin and other popular medications. As a result manufacturers and health experts have expressed concerns that the cancer-causing chemical byproduct may be a widespread contaminant throughout the U.S. drug supply.

NDMA is considered a carcinogen, and is mostly known as a byproduct of making rocket fuel. Howver, today it is primarily only used in laboratory experiments to induce cancer in animal test subjects.

Detection of the NDMA problems in a widely distributed heartburn and blood pressure drugs have resulted in Zantac recallsgeneric valsartan recalls and other regulatory actions after it was confirmed that levels of NDMA present in the pills exceed the threshold determined to be safe by federal regulators.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

On April 20, a report by Chemical & Engineering News warned that pharmaceutical industry experts are concerned about how prevalent NDMA may be among their drug products, since many have never actually tested for the cancer-causing chemical despite their products being on shelves for years, and despite indications that some manufacturers knew NDMA was likely present in their drugs for decades.

The companies now face pressure from the FDA to explain how future contamination can be prevented, both from NDMA and other harmful contaminants as well.

In some cases, such as with valsartan and other sartan-based drugs, which are prescribed as hypertension treatments, NDMA was introduced to the medication as part of the manufacturing process. However in other drugs, like Zantac’s active ingredient ranitidine, it appears to be a byproduct of chemical processes created by the drug itself.

According to the report, many means of detecting NDMA did not exist until recently, which has made finding NDMA in long-used drugs much easier. However, according to allegations raised in a number of recently lawsuits, some manufacturers knew or should have known about the presence of NDMA for decades.

In hundreds of recently filed Zantac lawsuits brought by former users of the heartburn drug diagnosed with cancer, plaintiffs allege that the pharmaceutical industry had information for decades that suggested NDMA may be created as a byproduct of ranitidine’s exposure to heat, either in the body or during storage. This means that users were likely exposed to the carcinogen since the blockbuster drug was introduced in the 1980s.

The European Medicines Agency and Health Canada have put out guidelines requiring drug manufacturers to conduct NDMA risk evaluations. The EMA guidelines were issued in September 2019 and the Health Canada guidelines were released in December 2019.

To date, no similar guidelines have been issued by the FDA.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns
Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns (Posted today)

The FDA has issued a safety communication warning that Zimmer Biomet CPT hip system femoral stems may increase the risk of femur fractures, calling for doctors to avoid its use when possible.

Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference
Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference (Posted yesterday)

The judge presiding over all Change Healthcare lawsuits filed in federal court is holding the first status conference of the litigation, which is expected to grow significantly as Change Healthcare data breach letters continue to be sent to impacted customers.

Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury
Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury (Posted 2 days ago)

Complaint comes as a panel of federal judges are scheduled to hear oral arguments later this month, to determine whether all AngioDynamics port catheter lawsuits filed in U.S. District Courts nationwide should be centralized before one judge.